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Nicole Birninger, Martin Bornh€auser, Markus Schaich, Gerhard Ehninger, Johannes ScheteligIn the context of allogeneic hematopoietic cell transplantation (allo-HSCT), comorbidities are an important
risk factor. Use of the hematopoietic cell transplantation-specific comorbidity index (HSCT-CI), which was
developed and validated in Seattle, Washington, has been proposed to predict the probability of nonrelapse
mortality (NRM) and overall survival (OS) following allo-HSCT. We performed a single-center retrospective
study to validate the prognostic impact of HSCT-CI on transplant outcomes in a cohort of high-risk acute
myeloid leukemia patients undergoing allo-HSCT between January 2000 and December 2008. The median
patient age at the time of transplantation was 53 years (range: 11-76 years). The median pretransplantation
HSCT-CI score was 4 (range: 0-10). Among 340 patients, OS at 3 years was 29% (95% confidence interval
[CI]: 17%-41%), 40% (33%-47%), and 44% (41%-47%) in the low-, intermediate-, and high-risk HSCT-CI
groups (P 5 .7), respectively. The corresponding NRM at 3 years was 34% (10%-58%), 32% (20%-44%),
and 26% (20%-32%; P 5 .6). In multivariate analysis, we found no predictive value of HSCT-CI for either
OS or NRM. The use of HSCT-CI as a decision-making tool for transplantation eligibility should not be con-
sidered until its validity has been unequivocally shown in crossvalidation studies.
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transplantation-specific comorbidity indexINTRODUCTION
Since the first transplantation of hematopoietic
stem cells in the 1960s, the number of patients who
receive allogeneic hematopoietic cell transplantation
(allo-HSCT) has continuously increased [1]. Despite
its success, the procedure is associated with significant
nonrelapse mortality (NRM).
In view of the diversity of potential interactions
between comorbidities and the transplantation proce-
dure, reliable information regarding the prognostic im-Medical Department I, University Hospital Carl Gustav
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6/j.bbmt.2011.06.009pact of comorbidities is desirable. The heterogeneity of
disease- and patient-specific characteristics as well as
classification systems complicates clinical decisionmak-
ing. Who should get a transplant with respect to ad-
vanced age and comorbidities remains a valid question.
To provide tools for physicians to address this issue,
several scoring systems have been developed. To date,
none of these methods has become a clinical standard
in the pretransplantation decision-making process.
The hematopoietic cell transplantation-specific
comorbidity index (HSCT-CI) was specifically devel-
oped to analyze pretransplantation comorbidities and
has been proposed to effectively predict the probability
of NRM and overall survival (OS) in allo-HSCT
recipients [2].
Since its development, HSCT-CI has been evalu-
ated at different institutions for various hematologic
diseases (eg, acute myeloid leukemia [AML] [3,4]
and lymphoproliferative disorders [5]), stem cell sour-
ces (umbilical cord blood [6]), autologous HSCT
[7,8], and even nontransplantation settings (AML
induction). However, its predictive potential has not
been uniformly confirmed [6,9-11] (Table 1).
Table 1. Previous Studies That Included HSCT-CI
Author (ref.)
Year
Published
No. of Patients
Studied Diagnosis
2-Year OS According
to HSCT-CI (%)
P Value
2-Year NRM According
to HSCT-CI (%)
P ValueLow Inter. High Low Inter. High
Sorror et al. [2] 2005 364 (validation set) various 71 60 34 .001 14 21 41 <.001
Sorror et al. [4] 2007 244 AML CR1 80 48 33 <.00 7 20 32 <.00
Sorror et al. [3] 2007 577 AML, MDS 64 35 <.001 11 33 <.001
Majhail et al. [6] 2008 373 various 72 59 48 <.01 10 22 28 <.01
Guilfoyle et al. [10] 2008 187 various 45 55 42 .76 36 26 30 .60
Farina et al. [5] 2009 203 lymphoma,
multiple myeloma
87 51 49 <.001 6 24 27 .04
DeFor et al. [27] 2009 444 various 62 58 50 .08 18 23 27 .12
Terwey et al. [11] 2010 151 ALL 58 50 46 .20 23 24 30 .11
Kataoka et al. [29] 2010 187 various 70 60 39 <.01 10 21 28 .03
Barba et al. [26] 2010 194 various 54 59 49 .43 15 18 31 .55
Castagna et al. [9] 2010 63 various ($60 years) 64 68 69 .98 na .2
Patel et al. [30] 2010 52 various 86 59 50 .1 14 23 1 14 .69
Smith et al. [31] 2011 252 various (#20 years) 88 67 62 <.01 10 14 28 <.01
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CR1, first complete remission; MDS, myelodysplastic syndrome; na, not
applicable.
Biol Blood Marrow Transplant 17:1822-1832, 2011 1823Crossvalidation of HSCT-CI in allo-HSCTThe major limitations of many of these validation
studies have been small sample sizes and the inclusion
of patients with heterogeneous diseases.
Before HSCT-CI can be utilized as a decision-
making tool or to predict outcomes, its applicability to
patient cohorts in various institutions with different re-
ferral characteristics must be demonstrated. Generally,
this type of verification is an indispensible requirement
before applying a scoring system on a uniform world-
wide basis.
The main objective of this study was to investigate
patient outcomes in relation to comorbidities assessed
by HSCT-CI in the context of well-defined disease-
specific characteristics. Therefore, we performed a
single-center, retrospective, cohort analysis restricted
to patients with AML.MATERIALS AND METHODS
Study Population
The current analysis represents a single-center
retrospective study. The inclusion criterion was
AML diagnosed according to World Health Organi-
zation (WHO) criteria and allo-HSCT performed at
our institution, a large German transplant unit with
a special focus on the treatment of AML, between
January 2000 andDecember 2008. This unit is charac-
terized by a high level of coordination with the hema-
tology department and receives a large proportion of
referred high-risk patients through national study
activities related to AML. Patients who had received
cord blood HSCT, haploidentical HSCT, or second
allo-HSCT were excluded.
The study was approved by the institutional review
board, and written informed consent for the analysis ofclinical data was obtained from the patients and/or
their parents.
A trained data manager extracted baseline trans-
plantation variables from the local computer database
system. Supplementary and missing data were col-
lected after a comprehensive review of medical records
by 1 of the investigators (N.B.). A senior hematologist
with expertise in stem cell transplantation supervised
the process of data extraction and assignment of
comorbidity scores. Missing echocardiography or
pulmonary function test data led to exclusion because
of inconclusive HSCT-CI assessment.
During the study period, a risk-adapted transplan-
tation strategy was applied depending on the risk of the
disease and donor availability. AML risk was defined as
follows: low risk: presence of either t(8;21) or inv(16)/
t(16;16); standard risk: normal karyotype, neither low-
risk nor high-risk abnormalities; high risk: (presence of
any of the following) 25, del(5q), 27, inv(3q), t(3;3),
t(6;9), t(6;11), t(11;19)(q23;p13.1), 18 (as single cyto-
genetic aberrations), $3 cytogenetic abnormalities
(complex karyotype), FLT3 ratio (mutated to wild
type).0.8, or.10% bonemarrow blast at day 15 after
induction therapy.
Patients with intermediate cytogenetic risk
AML without additional high-risk features received
allo-HSCT only if they had a human leukocyte antigen
(HLA)-matched sibling. For patients with standard-risk
cytogenetic abnormalities but FLT3 positivity or poor
day 15 bone marrow blast clearance, transplantation in
aplasia after induction chemotherapy with the use of
a matched sibling or an alternative donor was 1 of the
therapeutic options. In first remission, myeloablative
conditioning was considered standard for patients be-
low the age of 60 years in the absence of significant
comorbidities. Reduced-intensity conditioning (RIC)
1824 Biol Blood Marrow Transplant 17:1822-1832, 2011N. Birninger et al.regimens were offered to patients .60 years old and
those with preexisting significant medical problems.
In the context of transplantation in aplasia, RIC with
fludarabine and melphalan was the preferred regimen
[12].
Follow-up was terminated on September 31, 2009.
Data regarding patients were censored at the end of
their follow-up or at death.Definitions
The definition of de novo AML excluded patients
with previous malignancies. The definition of second-
ary AML included patients with a history of myelodys-
plastic syndrome (MDS), or exposure to chemotherapy
or radiation therapy.
Karnofsky performance scores (KPS) were catego-
rized as good ($80%) or poor (\80%) in accordance
with an earlier report [13].
The status before HSCT was defined as complete
remission (CR) if the bone marrow aspirate contained
\5% of marrow blasts. The cytogenetic risk groups
were reclassified according to the European Leukemia
Net (ELN) classification.
The risk of cytomegalovirus (CMV) infection was
divided into 3 categories as follows: seropositive pa-
tients, seronegative patients with seropositive donors,
and seropositive patients with seronegative donors.
Patients who had received more than 800 cGy
total body irradiation (TBI), more than 150 mg/m2
melphalan, or more than 10 mg/kg busulphan were
considered to have had high-dose conditioning. RIC
was defined as inclusion of #800 cGy TBI, #150
mg/m2 melphalan, or #10 mg/kg busulphan.
HLA matching between donors and recipients was
categorized into 3 groups according to the International
BoneMarrowTransplant Registry recommendations as
follows: HLA-identical sibling, HLA-matched unre-
lated (8 of 8 alleles matched), or partially mismatched
unrelated donor-recipient pairs [14].
Diagnosis and clinical grading of acute and chronic
graft-versus-host disease (aGVHD, cGVHD) were
performed using standard criteria [15-17].Performance Status and Comorbidities
Data on pretransplantation comorbidities were ex-
tracted by review of medical records and information
obtained from the local database system. Pulmonary
function tests as well as echocardiographic evaluation
of left ventricular ejection function and heart valve
diseases were performed as part of the pretransplanta-
tion routine workup. Diffusion capacity for carbon
monoxide was adjusted for hemoglobin levels [18].
Laboratory test results taken within 7 days before the
beginning of a conditioning regimen were considered
when calculating the comorbidity index.The investigator who assigned comorbidity scores
was blinded to the transplant outcome at the time of
assessment.
Comorbidities were categorized according to the
HSCT-CI classification. Each patient was assigned
a comorbidity score with no upper limit and strati-
fied into 1 of 3 risk groups based on their total
scores (q.v. Definitions). The comorbidity scores
were stratified into low risk (0 points), intermediate
risk (1-2 points), and high risk ($3 points) on the
basis of total scores.
KPS had been assessed and documented by the
treating hematologist/oncologist.Statistical Methods
Survival times were calculated from transplanta-
tion to the last day of follow-up. Probabilities of OS
and event-free survival (EFS) were calculated with
the Kaplan-Meier method. All patients, including
those who were not in remission before HSCT were
included in the analysis of EFS. Death from any cause
or relapse were considered as events.
Probabilities of NRM, relapse rate, and aGVHD
as well as cGVHD were calculated with the use of
the cumulative incidence function [19]. NRM and
relapse were considered as competing events. For
GVHD, death without GVHD was the competing
event. Data regarding patients who were alive without
an event were censored.
The influence of HSCT-CI and transplant
outcomes was evaluated using multivariate Cox
proportional-hazards regression for OS. NRM was
analyzed using univariate and multivariate competing
event statistics by Fine and Gray [20]. Variables
considered in multivariate analysis were age, AML
type, cytogenetic risk, donor type, gender constella-
tion, CMV serostatus, KPS, remission status, treat-
ment status, and HSCT-CI.
Relative risk estimates with 95% confidence inter-
vals (CIs) and respective P values were reported on
the basis of these analyses. All P values were 2 sided.
All statistical calculations were performed using
the software programs PASW Statistics 17 (SPSS,
Inc., Chicago, IL) and R 2.10.1 (The R Foundation
for Statistical Computing, 2010) [21].RESULTS
Patient Characteristics
We reviewed the records of 370 AML patients who
underwent allo-HSCT at our institution between
2000 and 2008. Of 370 eligible patients, 30 did not
have adequate data regarding pretransplantation co-
morbidities available to assess the HSCT-CI score;
Table 2. Patient Characteristics
Characteristics No. %
Total no. 340
Median age at HSCT (range)
53 (11-76 years)
Type of AML
De novo 232 68.2
History of myelodysplasia 87 25.6
Therapy associated 21 6.2
Cytogenetic risk
Low risk 14 4.1
Intermediate risk 212 62.4
High risk 104 30.6
Unknown/missing 10 2.9
Treatment status
Primary treatment (CR, PR,
refractory)
262 77.1
First relapse 57 16.8
Second or subsequent relapse 10 2.9
No prior chemotherapy 11 3.2
Blast count before HSCT
<5% 204 60.0
5%-20% 54 15.9
>20% 62 18.2
Karnofsky performance status
80%-100% 308 90.6
#70% 32 9.4
HSCT-CI
Low (0 points) 18 5.3
Intermediate (1-2 points) 70 20.6
High ($3 points) 252 74.1
Gender constellation
Female donor/male recipient 45 13.2
Other 295 86.8
CMV serostatus
Positive donor 201 59.1
Negative recipient/negative donor 88 25.9
Negative recipient/positive donor 51 15.0
Prior HSCT
No prior HSCT 316 92.9
Prior autologous PBSC 24 7.1
Stem cell source
PBSC 323 95.0
Bone marrow 17 5.0
Conditioning regimen
High dose 137 39.7
16 mg Bu/Flu 62 18.2
Bu/Cy 25 7.4
12 Gy TBI/Cy 36 10.5
Other 12 4.2
Reduced intensity 205 60.3
Flu/Mel 76 22.4
8 mg Bu/Flu 11 3.2
Bu/Flu/Rh-CD66/Campath 31 9.1
8 Gy TBI/Flu 68 20.0
Other 19 5.7
T cell depletion
No TCD 221 65.0
Use of ATG 80 23.5
Use of Campath 30 8.8
Ex vivo TCD 9 2.6
HLA compatibility
Matched siblings 116 34.1
MUD (8/8) 130 38.2
Mismatched donor 94 27.6
GVHD prophylaxis
CSA Monotherapy 114 33.5
Calcineurin inhibit. + MTX/MMF 206 60.6
Calcineurin inhibit. +/2 mTOR
inhibit.
20 5.9
Median graft content CD34+  10/kg (range)
6.5 (0.89-13.60)
Biol Blood Marrow Transplant 17:1822-1832, 2011 1825Crossvalidation of HSCT-CI in allo-HSCTtherefore, the final study cohort consisted of data sets
from 340 patients.
Patient clinical baseline characteristics are shown
in Table 2. The median age at HSCT was 53 years
(range: 11-76 years) and increased from 42 years in
2000 to 57 years in 2008 (Mann-Whitney U test, P 5
.001) (Figure 1). A total of 68% of patients had de
novo AML, 26% had AML arising out of MDS, and
6% had therapy-related disease. Among all patients,
86 (26%) were in first complete remission (CR-1) of
standard-risk AML and 45 (14%) were in CR-1 of
high-risk AML, whereas the remainder had more ad-
vanced disease. Of these, 67 (20%) patients received
transplantation in aplasia following induction therapy;
36 (11%) patients were in CR-2 at the time of HSCT;
and 93 (27%) patients were in partial response or had
refractory disease, including 26 (8%) patients with
a blast-free marrow stage (\5% of marrow blasts).
Because of the high level of coordination with the
Hematology Department, the interval between first
diagnosis and transplantation was relatively short
(median, 3.3 months; range: 0.5-15.8 months). The
use of high-dose conditioning regimes increased
from 33% in 2000 to 82% in 2008. Donors were
HLA-identical siblings in 116 patients (34%), matched
unrelated donors in 130 patients (38%), and partially
matched donors in 94 patients (28%). Because of
changes in treatment algorithms over time, the num-
ber of unrelated donors increased from 48% in 2000
to 71% in 2008 (P 5 .001, chi-square).
HSCT-CI
In our study population, hepatic dysfunction
(51%), heart valve disease (44%), and infections
(45%) were the comorbidities most commonly ob-
served.
Hepatic dysfunction was classified as mild in 38%
of the patients andmoderate-severe in 13%of patients.
In 80 patients (24%), a single regurgitant valve
was detected, including 77 (23%) patients with grade
1 severity and 3 (1%) with grade 2 severity. Two regur-
gitant valves, almost exclusively grade 1 (13%) or
grade 2 regurgitation (3%), were observed in 54 pa-
tients (16%); 3 regurgitant valves were detected in
17 patients (5%), including predominantly 4% grade
1 severity and 1% grade 2 regurgitation. By definitionAML indicates acute myeloid leukemia; CR, complete remission; PR, par-
tial response; HSCT, hematopoietic stem cell transplantation; HSCT-CI,
hematopoietic cell transplantation-specific comorbidity index; CMV,
cytomegalovirus; PBSC, peripheral blood stem cells; TCD, T cell
depletion; ATG, antithymocyte globulin; CSA, cyclosporine A; MTX,
methotrexate, MMF, mycophenolate mofetil; MUD, matched unrelated
donor; HLA, human leukocyte antigen; GVHD, graft-versus-host
disease; Bu, busulfan; Flu, fludarabin; Cy, cyclophosphamide; TBI,
total body irradiation; Mel, melphalan; Rh-CD66, rhenium-anti-CD66
globulin.
Figure 1. Demographic change of age per year. In panel 1, the demo-
graphic change of age in patients receiving hematopoietic stem cell
transplantation (HSCT) per year is shown. The median age at HSCT
was 53 years (range: 11-76 years) and increased from 42 years in
2000 to 57 years in 2008.
1826 Biol Blood Marrow Transplant 17:1822-1832, 2011N. Birninger et al.of the HSCT-CI, 45% of the patients thus had a mini-
mumHSCT-CI score of 3 based on heart valve disease.
Regarding infectious comorbidity, 5% of patients
experienced fevers of unknown origin, and 40% of pa-
tients had clinical evidence of an infectious disease at
the time of conditioning. Details regarding infections
were as follows: 9% of patients had positive blood
cultures, 19% had infections of the upper or lower
respiratory tract (12% aspergillosis and 7% atypical
pneumonia or sinusitis), and 13% had other infections,
which included 1%with abscess-forming tissue, before
HSCT. Forty-four (66%) of 67 patients who were
transplanted in aplasia after AML induction therapy
suffered from infectious comorbidity compared with
110 (40%) of the 273 patients (chi-square, P\ .001).
Moderate/severe renal insufficiency was not
present in our cohort.
The HSCT-CI risk was low in 18 (5%), interme-
diate in 70 (21%), and high in 252 (74%) patients.
The median pretransplantation HSCT-CI score was
4 (range: 0-10), and the comorbidity score showed
no considerable change over time (Mann-Whitney
U test, P 5 .46).
The distribution of HSCT-CI scores in the sub-
group of patients receiving transplantation in aplasia
was low in 2 (3%), intermediate in 13 (19%), and
high in 52 (78%) patients, with a median comorbidity
index of 4 (range: 0-9).
Comparison to Published AML Series [4]
Compared with published data from the Fred
Hutchinson Cancer Research Center (FHCRC) and
the M.D. Anderson Cancer Center (MDACC) on the
performance of HSCT-CI in patients with AML, our
patients had more advanced disease with only 40% be-
ing transplanted in CR-1 (Table 3) [22]. In addition,compared with the FHCRC/MDACC cohort, in our
patients, the proportion of HSCT from unrelated do-
norswas higher (P\.001), less bonemarrowwas trans-
fused as a stem cell source (P\.001), and less high-dose
conditioning regimens (P\ .001) were administered.
The prevalence of comorbidities as assessed by
HSCT-CI was also higher in our cohort compared
with the FHCRC/MDACC cohort (Table 3). Upon
comparative consideration, hepatic impairment
(P\ .001), infection (P\ .001), and cardiac disease
(P\ .001) were found more frequently in our study
population.OS, EFS, and NRM
Survival endpoints were analyzed according to
HSCT-CI in a complete case evaluation of 311 pa-
tients. The median follow-up for survivors was 30
months (range: 0.6-111.1 months).
For the entire study cohort, 3-year OS was 29% in
low-risk (95% CI: 17%-41%), 40% in intermediate-
risk (33%-47%), and 44% in high-risk (41%-47%)
patients (P 5 .7). According to HSCT-CI 3-year
EFS was 27% (16%-38%), 38% (31%-45%), and
43% (40%-46%) in the low-, intermediate-, and
high-risk HSCT-CI groups (Figure 2). At 3 years,
NRM was 34% (10%-58%), 32% (20%-44%), and
26% (20%-32%) in the low-, intermediate-, and
high-risk HSCT-CI groups (P 5 .6) (Figure 3).
Two regression models were fitted to assess the
predictive capacity of the index for NRM and OS
among all patients. The first multivariate Cox regres-
sion model was adjusted for age, KPS, type of AML,
cytogenetic risk, treatment and remission status, gen-
der constellation, CMV constellation, donor type,
and conditioning intensity (see Table 4). Identical to
the publication by Sorror et al. [4], the second multi-
variate regression model included HSCT-CI, age,
stem cell source, cytogenetic risk, donor type, and con-
ditioning type (see Appendix). In both multivariate
models, HSCT-CI neither as a categoric (data not
shown) nor as a numeric variable contributed signifi-
cantly to predict OS and NRM.
To test whether the predictive value of HSCT-CI
was lost by a shift effect to higher scores, we entered
the comorbidity score with the full range of values
ranging from 0 to 10 as a numeric variable into the
regression models; however, we failed to demonstrate
an association between HSCT-CI and OS or NRM
(see Appendix).
To avoid overscoring comorbidities, we changed
the score assessment for heart valve disease to clinically
relevant findings. Even when we neglected grade 1
heart valve regurgitation (single or in combination),
the modified HSCT-CI did not significantly predict
OS and NRM (hazard ratio [HR] 1.01; P 5 .82 for
OS and HR 0.99; P 5 .94 for NRM).
Table 3. Patient and Disease Characteristics in Comparison with FHCR and MDACC [4]
Characteristics
Dresden
n 5 340
FHCRC
n 5 177
MDACC
n 5 67 Chi-square, P Value
Median age, years (range) 53 (11-76) 41 (19-75) 39 (19-67)
Cytogenetic risk, n (%) .002
SR in CR-1 88 (26) 150 (85) 43 (64)
HR in CR1 48 (14) 27 (15) 24 (36)
Conditioning regimen, n (%) <.001
High intensity 133 (39) 156 (89) 45 (67)
Low intensity 207 (61) 21 (12) 22 (32)
Stem cell source, n (%) <.001
PBSC 323 (95) 115 (65) 39 (58)
BM 17 (5) 62 (35) 28 (42)
Donor type, n (%) <.001
Sibling 116 (34) 120 (68) 52 (78)
Matched UD 129 (38) 39 (22) 10 (15)
Mismatched donor (related and unrelated) 95 (28) 18 (10) 5 (7)
Patient CMV serostatus, n (%) .16
Negative 139 (41) 80 (45) 21 (32)
Positive 201 (59) 97 (55) 46 (68)
HSCT-CI, n (%) <.001
Low (0 points) 17 (5) 90 (51) 14 (21)
Intermediate (1-2 points) 71 (21) 50 (28) 14 (21)
High ($3 points) 252 (74) 37 (21) 39 (58)
Comorbidities, n (%)
Pulmonary 116 (34) 46 (26) 31 (46) .06
Hepatic 173 (51) 25 (14) 20 (30) <.001
Cardiac 190 (56) 12 (7) 11 (16) <.001
GI 7 (2) 7 (4) 1 (1) .37
Prior malignancy 31 (9) 11 (6) 13 (19) .02
Infection 153 (45) 12 (7) 7 (10) <.001
Depression 17 (5) 12 (7) 5 (7) .81
Obesity 7 (2) 5 (3) 11 (16) <.001
FHCR indicates Fred Hutchinson Cancer Research Center; MDACC, M.D. Anderson Cancer Center; SR, standard risk; HR, high risk; CR-1, first
complete remission; PBSC, peripheral blood stem cells; BM, bone marrow; UD, unrelated donor; CMV, cytomegalovirus; HSCT-CI, hematopoietic
cell transplantation-specific comorbidity index; GI, gastrointestinal.
Biol Blood Marrow Transplant 17:1822-1832, 2011 1827Crossvalidation of HSCT-CI in allo-HSCTFurthermore, models were fitted with modified
HSCT-CI scores disregarding heart valve disease of
any grade and/or infection completely (data not
shown). Again, these modifications of the scoring
procedure did not improve the performance of the
HSCT-CI in our cohort.
In the multivariate analysis of the first model, age,
KPS, remission status, and donor type were associated
with OS. In addition, age, KPS, and donor type corre-
lated with NRM.Acute GVHD and cGVHD
The cumulative incidence of grade II-IV aGVHD
on day 1100 was 36% (31%-41%; n 5 107), and
grade III-IV aGVHD incidence was 20% (15%-24%;
n 5 39). The cumulative incidence of extensive and
limited cGVHD at 3 years was 51% (45%-56%;
n 5 53). When aGVHD II-IV was entered into the
Cox regression model as a time-dependent covariate,
the HR of HSCT-CI as a numeric covariate was 0.96
(0.89-1.04) for OS and 0.94 (0.84-1.04) for NRM. In
contrast, we found a strong association between grade
III-IV aGVHD and NRM (HR: 4.04, 2.34-6.98) and
OS (HR: 2.25, 1.50-3.37). Extensive and limited
cGVHD, entered as a time-dependent covariate, was
not associated with NRM or OS.DISCUSSION
Multiple efforts to identify risk factors and estab-
lish scores for NRM following transplantation have
been attempted. With respect to comorbidities, the
most recognized undertaking has been made by
FHCRC with the HSCT-CI, an adapted geriatric as-
sessment scale. The index showed remarkable predic-
tive capacity in a validation cohort of patients from
FHCRC. However, cross-center validation of the in-
dex resulted in highly dissimilar conclusions with re-
gard to its predictive capacity.
Here, we evaluated a large cohort of mostly
high-risk, elderly AML patients. Surprisingly, the
HSCT-CI had virtually no predictive value with
regard to this dataset. Neither inclusion of the
HSCT-CI as a categoric variable adopting the classic
definitions of low-, intermediate-, and high-risk co-
morbidities, nor its use as a continuous variable dem-
onstrated adequate discrimination. The fact that we
analyzed mostly elderly patients with high-risk AML,
whereas the index had originally been developed and
validated in standard-risk patients, should not influ-
ence the performance of HSCT-CI with respect to
NRM. GVHD could have overridden the effect of
comorbidities on NRM; however, this possibility is
unlikely because the performance of the index did
Figure 3. Cumulative incidence of non-relapse mortality (NRM) according
to HSCT-CI risk groups. Cumulative incidence plots of NRM in the
3 HSCT-CI risk groups. At 3 years, NRM was 34% (95% CI:
10%-58%), 32% (95% CI: 20%-44%), and 26% (95% CI: 20%-32%) in
the low-, intermediate-, and high-risk HSCT-CI groups (P 5 .6). A com-
parison of the NRM rates did not result in a significant difference in any
of the risk groups. The low-risk group (0 index points) is represented by
blue, the intermediate-risk group (1-2 index points) by red, and the high-
risk group ($3 index points) by green lines.
Figure 2. Overall survival (OS) according to HSCT-CI risk groups. Kaplan-
Meier plots of OS in the 3 index risk groups stratified by intensity of
the conditioning regimen. For the entire study cohort, 3-year OS was
29% in low-risk (95% CI: 17%-41%), 40% in intermediate-risk (95% CI:
33%-47%), and 44% in high-risk (95% CI: 41%-47%) patients according
to HSCT-CI (P5.7). A comparison of theOS rates did not result in a sig-
nificant difference in any of the risk groups. The low-risk group (0 index
points) is represented by blue, the intermediate-risk group (1-2 index
points) by red, and the high-risk group ($3 index points) by green lines.
1828 Biol Blood Marrow Transplant 17:1822-1832, 2011N. Birninger et al.not improve after inclusion of grade III-IV aGVHD as
a time-dependent covariate in the multivariate model.
Notably, comorbidity in our cohort was distrib-
uted differently compared with the Seattle and Hous-
ton AML patient cohorts [4]. Our patients suffered
from more hepatic, cardiac, and infection-related co-
morbidities, which could be partially related to
a shorter interval between induction chemotherapy
and allo-HSCT compared with the Seattle and Hous-
ton cohorts. Notably, 20% of our patients were trans-
planted in aplasia after intensive induction therapy. By
definition, infectious comorbidities occurred fre-
quently in our cohort, most likely as a result of the
short interval between induction chemotherapy and
transplantation. It may well be that findings leading
to the assignment of comorbidities represent different
pathologies in our cohort compared with the original
cohort. Transiently elevated liver enzymes because of
residual chemotherapy toxicity or concomitant antibi-
otic treatment could be less predictive compared with
persistently elevated liver enzymes because of chronic
conditions after a longer interval from the last treat-
ment. Another reason for more hepatic comorbidities
in our cohort could be the increasing use of voricona-
zole as secondary prophylaxis in patients with a history
of invasive fungal infections. Prophylactic administra-
tion of posaconazole since 2007 frequently resulted in
elevated liver enzymes.
The apparent differences between our cohort and
the FHCRC cohort may also be related to morecomplex reasons such as the socioeconomic status
[23]. In contrast to the United States, our population
of HSCT recipients comes from a public healthcare
system providing equal access to medical treatment,
whereas in the United States access to HSCT is influ-
enced to some extent by insurance coverage, which is,
in turn, related to socioeconomic and demographic
factors [24].
The higher prevalence of heart valve disease
(predominantly grade 1, single-valve regurgitation)
in our patients is concordant with frequencies reported
in the general population [25]. This points to the pos-
sibility that different working definitions could have
been applied by data managers to assess comorbidities.
Moreover, echocardiographic assessment of heart
valve disease is subject to considerable interobserver
variability. Refined definitions regarding the timing
of laboratory investigations and function tests (eg,
whether the diffusion capacity for carbon monoxide
should be adjusted for hemoglobin levels or not) could
be beneficial. A manual providing detailed definitions
on assessment of comorbidities could be helpful to
avoid overscoring and to increase reliability.
Another potential limitation of the index are the
cutoff points for low, intermediate, and high risk.
Data from several recent reports indicate that a modi-
fied or flexible HSCT-CI can increase its predictive
power. Barba et al. [26] used a different risk group
stratification with empirical aspects. DeFor et al. [27]
proposed fundamental changes replacing the original
categorical weights withHRs frommultivariate regres-
sion models. Both authors suggest that modification or
Table 4. Multivariate Regression Analysis Stratified for Dose Intensity (n 5 311)
No.
OS NRM
HR (95% CI) P Value HR (95% CI) P Value
Age 311 1.02 (1.0-1.03) .016 1.02 (1.01-1.03) .04
Karnofsky performance status .005 .005
Good (80%-100%) 285 1.00 1.00
Poor (#70%) 26 2.02 (1.34-3.31) 2.93 (1.49-5.76)
HSCT-CI 311 0.97 (0.89-1.04) .36 0.95 (0.90-1.01) .37
AML type .83 .20
de novo AML 212 1.00 1.00
sAML/tAML 99 1.04 (0.73-1.48) 1.41 (1.14-1.67)
Cytogenetic .15 .45
Standard risk 210 1.00 1.00
High risk 101 1.27 (0.91-1.77) 0.98 (0.59-1.61)
Treatment status .49 .86
Primary therapy 253 1.00 1.00
First/subsequent relapse 58 1.16 (0.75-1.80) 1.06 (0.72-1.40)
Remission status
<5% before HSCT 198 1.00 .003 1.00 .87
5%-20% before HSCT 53 1.33 (0.82-2.16) .25 0.82 (0.45-1.18) .58
>20% before HSCT 60 1.94 (1.33-2.85) .001 0.97 (0.67-1.26) .91
Gender constellation .86 .24
Other 270 1.00 1.00
Female donor 41 1.04 (0.66-1.65) 1.43 (1.12-1.73)
CMV serostatus
Pos. recipient 184 1.00 .57 1.00 .78
Neg. recipient/neg. donor 83 0.86 (0.58-1.23) .47 1.02 (0.74-1.31) .93
Neg. recipient/pos. donor 44 1.13 (0.72-1.78) .59 1.49 (1.18-1.82) .20
Donor
Related 109 1.00 .014 1.00 .005
UD (8/8) 120 1.14 (0.76-1.71) .51 1.67 (1.37-1.96) .08
mmUD 82 1.78 (1.19-2.67) .005 2.36 (2.06-2.66) .005
OS indicates overall survival; NRM, nonrelapse mortality; HSCT-CI, hematopoietic cell transplantation-specific comorbidity index; HR, hazard ratio;
HSCT, hematopoietic stem cell transplantation; sAML, secondary acute myeloid leukemia; tAML, therapy-related acute myeloid leukemia; CMV, cyto-
megalovirus; UD, unrelated donor; mmUD, mismatched unrelated donor.
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We considered the full range of scores in our cohort by
including the score as a numerical variable into the
model. However, even with this approach, we were
not able to confirm the predictive value of the index.
Therefore, we can exclude a simple shift effect because
of higher scores leading to insignificant results.
Notably, another cross-center validation study re-
stricted to AML patients failed to convincingly dem-
onstrate the predictive value of HSCT-CI. In 2007,
Sorror [4] published the combined FHCRC and
MDACC cohorts of AML CR-1 patients classified ac-
cording to HSCT-CI. The HSCT-CI did not predict
for NRM in the MDACC cohort despite huge statisti-
cal effects in the multivariate model (HSCT-CI inter-
mediate to HSCT-CI low: HR 4.9, 95% CI: 0.4-55).
Surprisingly, the HRs for patients with intermediate
risk were almost the same compared with those with
high risk in the MDACC cohort.
Here, we report on an independent validation
study restricted to AML patients. Unfortunately, we
were not able to confirm the predictive value of the
HSCT-CI index. In view of the huge statistical effects
of high HSCT comorbidity scores reported even for
the validation cohort of the original report (score of
3 compared with 0, HR 4.0, 95% CI: 2.1-7.5), smallsample size can be excluded as an explanation for not
observing statistically significant effects of comorbid-
ities assessed by HSCT-CI in this large cohort of
AML patients. More likely, the interinstitutional dif-
ferences discussed and data-dependence of HSCT-
CI need to be considered as explanations [28].
FHCRC took the lead to develop a scoring system
with the aim of predicting mortality following allo-
HSCT. To have such a tool available would be ex-
tremely helpful for patient selection and counseling
in the context of transplantation. For the first time,
a scoring system was recognized and applied world-
wide in heterogeneous populations of transplanted
patients. This prompted German authorities to start
using HSCT-CI to deny access to unrelated donor
searches and reimbursement for elderly patients before
crossvalidation of the index under local circumstances.
Our observations question this approach. Therefore,
further efforts to modify or adapt the index are war-
ranted. We highlight some aspects of HSCT-CI that
deserve clarification and refinement and argue for a co-
operative approach to further develop HSCT-CI un-
der various conditions.
In summary, HSCT-CI failed to predict OS and
NRM in a large cohort of elderly high-risk AML pa-
tients who were receiving allo-HSCT. The use of
1830 Biol Blood Marrow Transplant 17:1822-1832, 2011N. Birninger et al.the current version of HSCT-CI as a universally appli-
cable instrument to select and counsel patients for allo-
HSCT should be reconsidered in populations where
the index has not been validated.ACKNOWLEDGMENTS
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Table 5. Prevalence of Specific Comorbidities in Comparison
to Sorror et al. [2]
Comorbidities*
Current Study
Prevalence, %
Sorror et al.
Prevalence, %
Arrhythmia 4 5
Cardiac disease 8 5
Inflammatory bowel disease 1 1
Diabetes 6 3
Cerebrovascular disease 1 <1
Psychiatric disease 5 9
Mild hepatic dysfunction 38 16
Obesity 2 2
Infection 45 4
Rheumatologic 2 4
Peptic ulcer 1 1
Moderate/severe renal dysfunction 0 2
Moderate pulmonary dysfunction 23 24
Prior solid tumor 9 2
Heart valve disease 44 2
Severe pulmonary dysfunction 11 9
Moderate/severe hepatic dysfunction 13 4
*Comorbidities defined according to HSCT-CI.
Table 6. Multivariate Regression Analysis Stratified for Dose Intensity (Modified HSCT-CI), n 5 311
No.
OS NRM
HR (95%CI) P Value HR (CI 95%) P Value
Age 311 1.02 (1.0-1.03) .02 1.02 (1.0-1.04) .03
Karnofsky performance status .005 .002
Good (80%-100%) 285 1.00 1.00
Poor (#70%) 26 2.05 (1.25-3.35) 2.91 (1.47-5.67)
Modified HSCT-CI 311 1.01 (0.93-1.1) .82 0.99 (0.89-1.12) .94
AML type .86 .26
de novo AML 212 1.00 1.00
sAML/tAML 99 1.03 (0.72-1.47) 1.33 (0.81-2.19)
Cytogenetic .16 .96
Standard risk 210 1.00 1.00
High risk 101 1.27 (0.91-1.77) 0.99 (0.60-1.62)
Treatment status .5 .75
Primary therapy 253 1.00 1.00
First/subsequent relapse 58 1.16 (0.75-1.79) 1.11 (0.59-2.08)
Remission status
<5% before HSCT 198 1.00 .003 1.00 .78
5%-20% before HSCT 53 1.33 (0.82-2.16) .25 0.96 (0.48-1.89) .89
>20% before HSCT 60 1.95 (1.33-2.85) .001 1.21 (0.67-2.19) .53
Gender constellation .79 .36
Other 270 1.00 1.00
Female donor 41 1.06 (0.67-1.68) 1.32 (0.72-2.42)
CMV serostatus
Pos. recipient 184 1.00 .65 1.00 .46
Neg. recipient/neg. donor 83 0.88 (0.59-1.31) .54 1.02 (0.58-1.79) .95
Neg. recipient/pos. donor 44 1.12 (0.72-1.76) .62 1.47 (0.78-2.77) .23
Donor
Related 109 1.00 .012 1.00 .02
UD (8/8) 120 1.12 (0.75-1.68) .57 1.62 (0.88-2.97) .12
mmUD 82 1.79 (1.19-2.68) .005 2.43 (1.32-4.49) .004
HSCT indicates hematopoietic cell transplant; UD, unrelated donor; mmUD, mismatched unrelated donor; CMV, cytomegalovirus; HSCT-CI,
hematopoietic cell transplantation-specific comorbidity index; NRM, nonrelapsemortality; OS, overall survival; HR, hazard ratio; CI, confidence interval;
AML, acute myeloid leukemia; sAML, secondary acute myeloid leukemia; tAML, therapy-related acute myeloid leukemia.
Table 8. Multivariate Regression Analysis According to the Original Publication [4] (Modified HSCT-CI; n 5 330)
No.
OS NRM
HR (95%CI) P Value HR (95% CI) P Value
Age 330 1.02 (1.00-1.03) .01 1.02 (1.00-1.04) .02
Stem cell source .69 .65
PBSC 314 1.00 1.00
Bone marrow 16 0.85 (0.41-1.79) 0.78 (0.28-2.19)
Modified HSCT-CI 330 1.01 (0.94-1.09) .70 1.00 (0.9-1.11) .99
Dose intensity .23 .83
High dose 129 1.00 1.00
Reduced intensity 201 0.82 (0.59-1.14) 1.05 (0.66-1.67)
Cytogenetic .08 .99
Standard risk 226 1.00 1.00
High risk 104 1.33 (0.97-1.81) 0.99 (0.62-1.60)
Donor
Related 115 1.00 .008 1.00 .014
UD (8/8) 125 1.19 (0.82-1.74) .35 1.56 (0.89-2.73) .123
mmUD 90 1.78 (1.23-2.59) .003 2.30 (1.31-4.04) .004
PBSC indicates peripheral blood stem cells; HSCT-CI, hematopoietic cell transplantation-specific comorbidity index; UD, unrelated donor; mmUD,
mixed matched unrelated donor; NRM, nonrelapse mortality; OS, overall survival; HR, hazard ratio; CI, confidence interval.
Table 7. Multivariate Regression Analysis According to the Original Publication [4] (n 5 330)
No.
OS NRM
HR (95%CI) P Value HR (95% CI) P Value
Age 330 1.02 (1.01-1.03) .007 1.02 (1.01-1.04) .01
Stem cell source .7 .64
PBSC 314 1.00 1.00
Bone Marrow 16 0.87 (0.42-1.79) 0.78 (0.28-2.19)
HSCT-CI 330 0.97 (0.91-1.04) .41 0.95 (0.86-1.01) .34
Dose intensity .20 .86
High dose 129 1.00 1.00
Reduced intensity 201 0.81 (0.58-1.12) 1.04 (0.66-1.65)
Cytogenetic .08 .98
Standard risk 226 1.00 1.00
High risk 104 1.33 (0.97-1.81) 0.99 (0.62-1.59)
Donor
Related 115 1.00 .01 1.00 .02
UD (8/8) 125 1.20 (0.83-1.75) .33 1.56 (0.89-2.74) .12
mmUD 90 1.77 (1.21-2.58) .003 2.27 (1.29-3.98) .004
PBSC indicates peripheral blood stem cells; HSCT-CI, hematopoietic cell transplantation-specific comorbidity index; UD, unrelated donor; mmUD, mis-
matched unrelated donor; NRM, nonrelapse mortality; OS, overall survival; HR, hazard ratio; CI, confidence interval.
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